Design Defect Claims Dismissed in Mass. Federal Singulair Action



DOCUMENTS
  • Order


BOSTON — A Massachusetts federal judge has dismissed design defect claims in an action alleging a link between Singulair (montelukast) and neuropsychiatric injuries, ruling they are preempted because defendants Merck and Organon could not make major changes to the drug’s design without FDA approval.

In a Jan. 4 order, Judge Nathaniel M. Gorton of the U.S. District Court for the District of Massachusetts dismissed the claims for both strict liability and negligent design defect.

Singulair was patented by Merck in 1996 and was approved by the FDA in 1998. Merck was the exclusive manufacturer, distributor and seller of Singulair from …

FIRM NAMES
  • Campbell Conroy & O'Neil PC
  • Justice Law Collaborative
  • Venable LLP
  • Wilentz Goldman & Spitzer





UPCOMING CONFERENCES




HarrisMartin's New Jersey Asbestos Litigation Conference

March 03, 2023 - New Brunswick, NJ
Hyatt Regency New Brunswick

MORE DETAILS



HarrisMartin's MDL Conference: Managing Mass Torts, Status of Key Litigations and Lessons Learned

March 29, 2023 - Tucson, AZ
Omni Tucson National Resort

MORE DETAILS